Genome-wide DNA methylation modified by soy phytoestrogens: Role for epigenetic therapeutics in prostate cancer?

OMICS A Journal of Integrative Biology

Volumn 19, Issue 4, 2015, Pages 209-219

  Karsli Ceppioglu, Seher ^a,b,c   Ngollo, Marjolaine ^a,b   Adjakly, Mawussi ^a,b   Dagdemir, Aslihan ^a,b   Judes, Gaëlle ^a,b   Lebert, André ^b   Boiteux, Jean Paul ^d   Penault Llorca, Frédérique ^a,b   Bignon, Yves Jean ^a,b   Guy, Laurent ^b,d   Bernard Gallon, Dominique ^a,b  

^a CENTRE JEAN PERRIN   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c MARMARA UNIVERSITY   (Turkey)

^d SERVICE DE RHUMATOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; BUDESONIDE; DAIDZEIN; GENISTEIN; PHYTOESTROGEN; SOY PHYTOESTROGEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; DNA; ISOFLAVONE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CULTURE; COMPARATIVE STUDY; DEMETHYLATION; DNA EXTRACTION; DNA HYBRIDIZATION; DNA METHYLATION; DNA MICROARRAY; DNA MODIFICATION; DRUG EFFECT; EPIGENETICS; GENE LOCUS; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LNCAP CELL LINE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; QUALITY CONTROL; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; PROSTATIC NEOPLASMS; SOYBEAN; TUMOR CELL LINE;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; AZACITIDINE; BUDESONIDE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA METHYLATION; DNA, NEOPLASM; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENISTEIN; HUMANS; ISOFLAVONES; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHYTOESTROGENS; PROSTATIC NEOPLASMS; SOYBEANS;

EID: 84926505813     PISSN: 15362310     EISSN: 15578100     Source Type: Journal    
DOI: 10.1089/omi.2014.0142     Document Type: Article

References (68)

1. Adjakly M, Bosviel R, Rabiau N, et al. (2011). DNA methylation and soy phytoestrogens: Quantitative study in DU-145 and PC-3 human prostate cancer cell lines. Epigenomics 3, 795-803.
2. Adjakly M, Ngollo M, Lebert A, et al. (2014). Comparative effects of soy phytoestrogens and 17beta-estradiol on DNA methylation of a panel of 24 genes in prostate cancer cell lines. Nutr Cancer 66, 474-482.
3. Akiyama M, Hideshima T, Hayashi T, et al. (2003). Nuclear factor-kappaB p65 mediates tumor necrosis factor alphainduced nuclear translocation of telomerase reverse transcriptase protein. Cancer Res 63, 18-21.
4. Ashour N, Angulo JC, Andres G, et al. (2014). A DNA hypermethylation profile reveals new potential biomarkers for prostate cancer diagnosis and prognosis. Prostate 74, 1171-01182.
5. Baker DJ, Jeganathan KB, Malureanu L, Perez-Terzic C, Terzic A, and van Deursen JM. (2006). Early aging-associated phenotypes in Bub3/Rae1 haploinsufficient mice. J Cell Biol 172, 529-540.
6. Bantscheff M, Hopf C, Savitski MM, et al. (2011). Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol 29, 255-265.
7. Beyer S, Kristensen MM, Jensen KS, Johansen JV, and Staller P. (2008). The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF. J Biol Chem 283, 36542-36552.
8. Carvalho B, Postma C, Mongera S, et al. (2009).Multiple putative oncogenes at the chromosome 20q amplicon contribute to colorectal adenoma to carcinoma progression. Gut 58, 79-89.
9. Chen RH, Brady DM, Smith D, Murray AW, and Hardwick KG. (1999). The spindle checkpoint of budding yeast depends on a tight complex between the Mad1 and Mad2 proteins. Mol Biol Cell 10, 2607-2618.
10. Choi YH, Zhang L, Lee WH, and Park KY. (1998). Genisteininduced G2/M arrest is associated with the inhibition of cyclin B1 and the induction of p21 in human breast carcinoma cells. Int J Oncol 13, 391-396.
11. Chun AC, and Jin DY. (2003). Transcriptional regulation of mitotic checkpoint gene MAD1 by p53. J Biol Chem 278, 37439-37450.
12. Coe BP, Lee EH, Chi B, et al. (2006). Gain of a region on 7p22.3, containing MAD1L1, is the most frequent event in small-cell lung cancer cell lines. Genes Chromosomes Cancer 45, 11-19.
13. Coffey K, Rogerson L, Ryan-Munden C, et al. (2013). The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover. Nucleic Acids Res 41, 4433-4446.
14. Dagdemir A, Durif J, Ngollo M, Bignon YJ, and Bernard-Gallon D. (2013). Histone lysine trimethylation or acetylation can be modulated by phytoestrogen, estrogen or anti-HDAC in breast cancer cell lines. Epigenomics 5, 51-63.
15. Davis JN, Kucuk O, Djuric Z, and Sarkar FH. (2001). Soy isoflavone supplementation in healthy men prevents NFkappa B activation by TNF-alpha in blood lymphocytes. Free Radic Biol Med 30, 1293-1302.
16. Domingo-Domenech J, Oliva C, Rovira A, et al. (2006). Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res 12, 5578-5586.
17. Dworkin AM, Huang TH, and Toland AE. (2009). Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment. Semin Cancer Biol 19, 165-171.
18. Fang MZ, Chen D, Sun Y, Jin Z, Christman JK, and Yang CS. (2005). Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy. Clin Cancer Res 11, 7033-7041.
19. Gao F, Ji G, Gao Z, et al. (2014). Direct ChIP-bisulfite sequencing reveals a role of H3K27me3 mediating aberrant hypermethylation of promoter CpG islands in cancer cells. Genomics 103, 204-210.
20. Graca I, Sousa EJ, Costa-Pinheiro P, et al. (2014). Anti-neoplastic properties of hydralazine in prostate cancer. Oncotarget 5, 5950-5964.
21. Guilleret I, Yan P, Grange F, Braunschweig R, Bosman FT, and Benhattar J. (2002). Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity. Int J Cancer 101, 335-341.
22. Herceg Z, and Vaissiere T. (2011). Epigenetic mechanisms and cancer: An interface between the environment and the genome. Epigenetics 6, 804-819.
23. Hillman GG, Wang Y, Kucuk O, et al. (2004). Genistein potentiates inhibition of tumor growth by radiation in a prostate cancer orthotopic model. Mol Cancer Ther 3, 1271-1279.
24. Iwanaga Y, Chi YH, Miyazato A, et al. (2007). Heterozygous deletion of mitotic arrest-deficient protein 1 (MAD1) increases the incidence of tumors in mice. Cancer Res 67, 160-166.
25. Jagadeesh S, Kyo S, and Banerjee PP. (2006). Genistein represses telomerase activity via both transcriptional and posttranslational mechanisms in human prostate cancer cells. Cancer Res 66, 2107-2115.
26. Jarrard DF, Kinoshita H, Shi Y, et al. (1998). Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res 58, 5310-5314.
27. Jeganathan K, Malureanu L, Baker DJ, Abraham SC, and van Deursen JM. (2007). Bub1 mediates cell death in response to chromosome missegregation and acts to suppress spontaneous tumorigenesis. J Cell Biol 179, 255-267.
28. Karsli-Ceppioglu S, Dagdemir A, Judes G, et al. (2014). Epigenetic mechanisms of breast cancer: An update of the current knowledge. Epigenomics 6, 651-664.
29. Kikuno N, Shiina H, Urakami S, et al. (2008). Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells. Int J Cancer 123, 552-560.
30. Kim NW, Piatyszek MA, Prowse KR, et al. (1994). Specific association of human telomerase activity with immortal cells and cancer. Science 266, 2011-2015.
31. Kote-Jarai Z, Saunders EJ, Leongamornlert DA, et al. (2013). Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum Mol Genet 22, 2520-2528.
32. Kyo S, Takakura M, Fujiwara T, and Inoue M. (2008). Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci 99, 1528-1538.
33. Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, and Sarkar FH. (2005). Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 65, 6934-6942.
34. Liu L, Saldanha SN, Pate MS, Andrews LG, and Tollefsbol TO. (2004). Epigenetic regulation of human telomerase reverse transcriptase promoter activity during cellular differentiation. Genes Chromosomes Cancer 41, 26-37.
35. Locksley RM, Killeen N, and Lenardo MJ. (2001). The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 104, 487-501.
36. Lopatina NG, Poole JC, Saldanha SN, et al. (2003). Control mechanisms in the regulation of telomerase reverse transcriptase expression in differentiating human teratocarcinoma cells. Biochem Biophys Res Commun 306, 650-659.
37. Luo JH, Ding Y, Chen R, et al., (2013). Genome-wide methylation analysis of prostate tissues reveals global methylation patterns of prostate cancer. Am J Pathol 182, 2028-2036.
38. Majid S, Dar AA, Shahryari V, et al. (2010). Genistein reverses hypermethylation and induces active histone modifications in tumor suppressor gene B-Cell translocation gene 3 in prostate cancer. Cancer 116, 66-76.
39. McCall P, Bennett L, Ahmad I, et al. (2012). NFkappaB signalling is upregulated in a subset of castrate-resistant prostate cancer patients and correlates with disease progression. Br J Cancer 107, 1554-1563.
40. Michel LS, Liberal V, Chatterjee A, et al. (2001). MAD2 haploinsufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature 409, 355-359.
41. New M, Olzscha H, and La Thangue NB. (2012). HDAC inhibitor-based therapies: Can we interpret the code? Mol Oncol 6, 637-656.
42. Ngollo M, Lebert A, Dagdemir A, et al. (2014a). The association between histone 3 lysine 27 trimethylation (H3K27me3) and prostate cancer: Relationship with clinicopathological parameters. BMC Cancer 14, 994-1010.
43. Ngollo M, Dagdemir A, Karsli-Ceppioglu S, et al. (2014b). Epigenetic modifications in prostate cancer. Epigenomics 6, 415-426.
44. Ouchi H, Ishiguro H, Ikeda N, Hori M, Kubota Y, and Uemura H. (2005). Genistein induces cell growth inhibition in prostate cancer through the suppression of telomerase activity. Int J Urol 12, 73-80.
45. Phillip CJ, Giardina CK, Bilir B, et al. (2012). Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells. BMC Cancer 12, 145.
46. Poole JC, Andrews LG, and Tollefsbol TO. (2001). Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene 269, 1-12.
47. Rabiau N, Kossai M, Braud M, et al. (2010). Genistein and daidzein act on a panel of genes implicated in cell cycle and angiogenesis by polymerase chain reaction arrays in human prostate cancer cell lines. Cancer Epidemiol 34, 200-206.
48. Regenbrecht CR, Jung M, Lehrach H, and Adjaye J. (2008). The molecular basis of genistein-induced mitotic arrest and exit of self-renewal in embryonal carcinoma and primary cancer cell lines. BMC Med Genomics 1, 49.
49. Ross JS, Kallakury BV, Sheehan CE, et al. (2004). Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: Correlation of nuclear factorkappa B immunoreactivity with disease recurrence. Clin Cancer Res 10, 2466-2472.
50. Rudolph KL, Chang S, Lee HW, et al. (1999). Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 96, 701-712.
51. Sasaki M, Tanaka Y, Perinchery G, et al. (2002). Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. J Natl Cancer Inst 94, 384-390.
52. Setlur SR, Royce TE, Sboner A, et al. (2007). Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer. Cancer Res 67, 10296-10303.
53. Shin KH, Kang MK, Dicterow E, and Park NH. (2003). Hypermethylation of the hTERT promoter inhibits the expression of telomerase activity in normal oral fibroblasts and senescent normal oral keratinocytes. Br J Cancer 89, 1473-1478.
54. Shin S, and Janknecht R. (2007). Activation of androgen receptor by histone demethylases JMJD2A and JMJD2D. Biochem Biophys Res Commun 359, 742-746.
55. Takeshima H, Wakabayashi M, Hattori N, Yamashita S, and Ushijima T. (2015). Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy. Carcinogenesis 36, 192-201.
56. Toedling J, Skylar O, Krueger T, Fischer J J, Sperling S, and Huber W. (2007). Ringo-An R/Bioconductor package for analyzing ChIP-chip readouts. BMC Bioinformatics 8, 221.
57. Tsukasaki K, Miller CW, Greenspun E, et al. (2001). Mutations in the mitotic check point gene, MAD1L1, in human cancers. Oncogene 20, 3301-3305.
58. Turashvili G, Bouchal J, Baumforth K, et al. (2007). Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 7, 55.
59. van Die MD, Bone KM, Williams SG, and Pirotta MV. (2014). Soy and soy isoflavones in prostate cancer: A systematic review and meta-analysis of randomized controlled trials. BJU Int 113, E119-130.
60. Van Poppel H, and Tombal B. (2011). Chemoprevention of prostate cancer with nutrients and supplements. Cancer Manag Res 3, 91-100.
61. Wang L, Wang L, Zhang S, et al. (2013). Downregulation of ubiquitin E3 ligase TNF receptor-associated factor 7 leads to stabilization of p53 in breast cancer. Oncol Rep 29, 283-287.
62. Wissmann M, Yin N, Muller J M, et al. (2007). Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol 9, 347-353.
63. Xu LG, Li LY, and Shu HB. (2004). TRAF7 potentiates MEKK3-induced AP1 and CHOP activation and induces apoptosis. J Biol Chem 279, 17278-17282.
64. Yu YP, Ding Y, Chen R, et al. (2013). Whole-genome methylation sequencing reveals distinct impact of differential methylations on gene transcription in prostate cancer. Am J Pathol 183, 1960-1970.
65. Yuan B, Xu Y, Woo JH, et al. (2006). Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res 12, 405-410.
66. Zhou JR, Gugger ET, Tanaka T, Guo Y, Blackburn GL, and Clinton SK. (1999). Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J Nutr 129, 1628-1635.
67. Zinn RL, Pruitt K, Eguchi S, Baylin SB, and Herman JG. (2007). hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site. Cancer Res 67, 194-201.
68. Zotti T, Uva A, Ferravante A, et al. (2011). TRAF7 protein promotes Lys-29-linked polyubiquitination of IkappaB kinase (IKKgamma)/NF-kappaB essential modulator (NEMO) and p65/RelA protein and represses NF-kappaB activation. J Biol Chem 286, 22924-22933.